Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by MustangSalleyon May 31, 2021 5:13pm
166 Views
Post# 33298041

RE:Buy Out

RE:Buy Out

Canada2016 wrote: With end of June looming I wonder if my pre conference buy out theory will come to fruition with the SP bleeding and management not caring to Mr. Fifty shades of Gray Dom accepting a new position with MRS. I don't know regardless end of June will be big. My expectations 7 patients fully enrolled and news from 3 patients insulin independent. And it's been forever kicking tires on a licensing deal. And better not be options announced at AGM without one.


Canada ,

First of all Dominic is a class act . He was the only one there that the investors trusted , spoke the truth and worked hard for the company . Can you blame him for leaving ? If you have great leadership you respect , you would stick around . Especially now when you think  Sernova might be at the cusp of something big.  Why would someone leave ?  Why pay Matthews $10 k a month for IR ?  Again more questions and answers for management .


Canada and all you guys that are in love with the stock and think management can walk on water , don't get too excited for the clinical results . Anything that is dependent on portal vein will be a diasappointment .  Anything positive will be sold into imo.

Maybe you guys should go on Sernova's webpage and see which prominent lead clinical management scientific person is no longer there ?

Maybe somebody should put the names of all the current staff on the AGM proxy to see how well functioning the team is.

Since there is no IR except Matthews and he is still getting paid to do nothing call him 604-818-7778 and ask him what's going on .

Ms. Sally 
 

<< Previous
Bullboard Posts
Next >>